Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Oral VK2735

Stage Phase 3Stale

Sponsor Viking Therapeutics, Inc

Route oral

Class GLP-1/GIP

Mechanism peptide GLP-1 and GIP dual agonist

Sources

registry, as of 2026-10-16Stale

https://clinicaltrials.gov/study/NCT07868939

Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2). Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Viking Therapeutics, Inc.. Enrollment 560. Conditions Weight Loss. This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.

ClinicalTrials.gov NCT07868939 protocol and results modules

registry, as of 2026-10-16Stale

https://clinicaltrials.gov/study/NCT07868835

Oral VK2735 for Weight Management Phase 3 (SUNRISE 1). Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Viking Therapeutics, Inc.. Enrollment 560. Conditions Weight Loss. This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type 2 diabetes mellitus.

ClinicalTrials.gov NCT07868835 protocol and results modules

registry, as of 2025-10-06Stale

https://clinicaltrials.gov/study/NCT06828055

VK2735 for Weight Management Phase 2 (Venture Oral Dosing). Overall status COMPLETED. Phases PHASE2. Lead sponsor Viking Therapeutics, Inc.. Enrollment 280. Conditions Weight Loss. This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg

ClinicalTrials.gov NCT06828055 protocol and results modules

registry, as of 2026-09-24Stale

https://clinicaltrials.gov/study/NCT07838740

A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities. Overall status RECRUITING. Phases PHASE1. Lead sponsor Viking Therapeutics, Inc.. Enrollment 270. Conditions Obese Adults. The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.

ClinicalTrials.gov NCT07838740 protocol and results modules

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07868939

Diabetes Mellitus (T2DM) who are obese or overweight. VK2735 Oral VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily Placebo Comparator Placebo comparator administered orally once daily

NCT07868939 description or intervention text

Studies

Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)

Registry NCT07868939

Phase Phase 3

Status Not yet recruiting

Enrollment 560

Placebo Assignment

Regimen once daily

Population Weight Loss

Active Assignment (Dose 1)

Regimen once daily

Comparator placebo

Population Weight Loss

Active Assignment (Dose 2)

Regimen once daily

Comparator placebo

Population Weight Loss

Active Assignment (Dose 3)

Regimen once daily

Comparator placebo

Population Weight Loss

Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)

Registry NCT07868835

Phase Phase 3

Status Not yet recruiting

Enrollment 560

Placebo Assignment

Regimen once daily

Population Weight Loss

Active Assignment (Dose 1)

Regimen once daily

Comparator placebo

Population Weight Loss

Active Assignment (Dose 2)

Regimen once daily

Comparator placebo

Population Weight Loss

Active Assignment (Dose 3)

Regimen once daily

Comparator placebo

Population Weight Loss

VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

Registry NCT06828055

Phase Phase 2

Status Completed

Enrollment 280

Start 2024-12-18

Primary completion 2025-06-24

Study completion 2025-08-15

Catalyst Primary completion. 2025-06-24. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Placebo Assignment

Regimen daily

Population Weight Loss

Active Assignment (Dose #1)

Regimen daily

Comparator placebo

Population Weight Loss

Active Assignment (Dose #2)

Regimen daily

Comparator placebo

Population Weight Loss

Active Assignment (Dose #3)

Regimen daily

Comparator placebo

Population Weight Loss

Active Assignment (Dose #4)

Regimen daily

Comparator placebo

Population Weight Loss

Active Assignment (Dose #5)

Regimen daily

Comparator placebo

Population Weight Loss

Active Assignment (Dose #6)

Regimen daily

Comparator placebo

Population Weight Loss

A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities

Registry NCT07838740

Phase Phase 1

Status Recruiting

Enrollment 270

Start 2025-11-18

Placebo

Regimen weekly

Population Obese Adults

VK2735 Dose Level 2

Regimen weekly

Comparator placebo

Population Obese Adults

VK2735 Dose Level 3

Regimen weekly

Comparator placebo

Population Obese Adults

VK2735 Dose Level 4

Regimen weekly

Comparator placebo

Population Obese Adults

VK2735 Dose Level 5

Regimen once monthly

Comparator placebo

Population Obese Adults

VK2735 Dose Level 6

Regimen once monthly

Comparator placebo

Population Obese Adults

VK2735 Dose Level 7

Regimen once monthly

Comparator placebo

Population Obese Adults

VK2735 Dose Level 8

Regimen once monthly

Comparator placebo

Population Obese Adults

VK2735 Dose Level 9

Regimen once monthly

Comparator placebo

Population Obese Adults

VK2735 Dose Level 10

Regimen weekly

Comparator placebo

Population Obese Adults

VK2735 Dose Level 11

Regimen weekly

Comparator placebo

Population Obese Adults

VK2735 Dose Level 12

Regimen weekly

Comparator placebo

Population Obese Adults

VK2735 Dose Level 14

Regimen once daily

Comparator placebo

Population Obese Adults

VK2735 Dose Level 15

Regimen once daily

Comparator placebo

Population Obese Adults

VK2735 Dose Level 16

Regimen once daily

Comparator placebo

Population Obese Adults

VK2735 Dose Level 17

Regimen once weekly

Comparator placebo

Population Obese Adults

VK2735 Dose Level 18

Regimen once daily

Comparator placebo

Population Obese Adults

VK2735 Dose Level 13

Regimen weekly

Comparator placebo

Population Obese Adults